Drug Approval | May 06, 2022
Zydus receives tentative approval from USFDA for Selexipag tablets
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
Glenmark Pharmaceuticals won Innovation of the Year award
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
The drug is indicated for use in combination with other drugs
It is only the second generic application approved by the USFDA
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Subscribe To Our Newsletter & Stay Updated
